Avior Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Avior Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45	Closed	-$939	–	1071
2024 Q4	$939	Hold	45	–	–	﹤0.01%	2204
2024 Q3	$894	Hold	45	–	–	﹤0.01%	2085
2024 Q2	$697	Sell	45 -19	-30%	-$296	﹤0.01%	2074
2024 Q1	$1.02K	Buy	64 +19	+42%	+$286	﹤0.01%	2395
2023 Q4	$756	Hold	45	–	–	﹤0.01%	1395
2023 Q3	$526	Hold	45	–	–	﹤0.01%	1487
2023 Q2	$604	Hold	45	–	–	﹤0.01%	1447
2023 Q1	$746	Hold	45	–	–	﹤0.01%	1484
2022 Q4	$837	Hold	45	–	–	﹤0.01%	1136
2022 Q3	$0	Hold	45	–	–	﹤0.01%	1166
2022 Q2	$0	Hold	45	–	–	﹤0.01%	1084
2022 Q1	$0	Hold	45	–	–	﹤0.01%	1116
2021 Q4	$0	Hold	45	–	–	﹤0.01%	1108
2021 Q3	$0	Buy	+45	New	+$246	﹤0.01%	1071

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Avior Wealth Management's CPRX Position: Q1 2025 in Review

Avior Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 45 shares — an estimated $939 sold.

Avior Wealth Management first reported a position in CPRX in Q3 2021 and held it in 14 quarters. The position peaked at $1.02K in Q1 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

Avior Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Avior Wealth Management sold 45 Catalyst Pharmaceutical shares in Q1 2025, an estimated $939.
Avior Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2021 and held it in 14 quarters.
Avior Wealth Management's Catalyst Pharmaceutical position peaked at $1.02K in Q1 2024.
371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.